Promising advancement in glioblastoma treatment offers new hope.
Tübingen, Germany – August 27, 2024 – Provenance Precision Medicine Foundation (PPMF) is excited to share a significant breakthrough in treating patients with glioblastoma (GBM), one of the deadliest forms of brain cancer.
A groundbreaking study conducted by an international team of investigators and published in the August issue of Nature demonstrates that personalized treatment with a neoantigen vaccine can improve immune response and extend survival in patients with this highly aggressive type of cancer. Spanning eight years and including 173 patients, the study now presents the largest real-world dataset on personalized neoantigen peptide vaccines for GBM.
The team, led by Dr. Saskia Biskup, MD, PhD, and co-founder of PPMF, created personalized vaccines using comprehensive tumor sequencing and analysis. Tailored to match specific mutations in each patient’s tumor—known as neoantigens—the vaccine enabled precise targeting of cancer cells by the immune system.
The published work demonstrated significant improvements in survival rates and immune responses within a diverse patient cohort, highlighting its potential to transform GBM therapy, extend its application to other cancers, and pave the way for further research, including, planned randomized, controlled trials to validate these findings, optimize the vaccine’s application, and explore its efficacy for other cancer types.
Regarding the impact of the data, Dr. Biskup stated, “Our aim is to make vaccines and immune therapies accessible to every cancer patient. Our vision is to even stay ahead of cancer cells through the use of prophylactic vaccines.”
Broadening Access to Treatment
Given the limited options currently available to treat GBM, patients travel at their own expense from around the world to access innovative therapies such as this. Their persistence and dedication underscore the critical unmet need for innovative therapies in glioblastoma, while the vaccine’s early success highlights the transformative potential of personalized medicine in addressing this urgent need.
Provenance Precision Medicine Foundation’s mission is to make personalized treatments more accessible by sharing information about these transformative, bespoke therapies with patients in the U.S. We are committed to highlighting pioneering efforts that extend patient survival and improve outcomes through tailored therapies.
To learn more about this personalized neoantigen vaccine and its potential to transform glioblastoma treatment, please visit the detailed report published in Nature.
Call to Action
To ensure we continue to provide patients with actionable information and equitable access to life-saving, cutting-edge, personalized medical treatments, we invite you to contribute to our mission. Your vital donation helps ensure that groundbreaking treatments continue to reach those in need. Please, spread the word.
Stay informed and be part of the breakthrough in glioblastoma therapy. Join us in supporting personalized medicine for a brighter future in cancer treatment.
Related Resources
Latzer, P. et al. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nat. Commun. 15, 6870 (2024).